CytoSorbents (CTSO)
Develops blood-purification cartridges for critical care and cardiac surgery, commercializing CytoSorb internationally.
$5.12
vs last close−0.20 (−3.76%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 25.68% | 806.9K shares | |
|---|---|---|---|
| 51 holders · as of Jun 30, 2026 | |||
| Insiders | 6.82% | 214.4K shares | |
| 6 holders · as of Sep 16, 2026 | |||
| Other | 67.50% | 2.12M shares | |
| remainder | |||
3.14M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
51 holders · 16.14M shares · 8 new positions · 20 increased · 13 reduced · 7 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Avenir Corp | 5.19M | 165.15% | −26.6K | Aug 13, 2026 |
| Neuberger Berman Group LLC | 1.97M | 62.65% | +285.7K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 1.91M | 60.92% | +34.1K | Aug 13, 2026 |
| CM Management, LLC | 1.48M | 46.99% | 0 | Aug 13, 2026 |
| Skylands Capital, LLC | 1.21M | 38.55% | −496.1K | Jul 24, 2026 |
| BlackRock, Inc. | 627.2K | 19.96% | −155.8K | Aug 7, 2026 |
| Geode Capital Management, LLC | 602.1K | 19.16% | −105.2K | Aug 12, 2026 |
| Sargent Investment Group, LLC | 555.8K | 17.69% | +5.9K | Aug 11, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Avenir Corp | 8.30% | 13G | Feb 13, 2026 | |
| Thomas A. Satterfield, Jr. | 6.56% | 13G | Jan 17, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 15, 2026 | Phillip P. Chandirector, officer: Chief Executive Officer | Purchase | 3,774 | $6.00 | 100,996 |
| Sep 15, 2026 | Alan D. Sobeldirector | Purchase · 3 lots | 2,500 | $6.10 | 9,887 |
| Sep 14, 2026 | Vincent Capponiofficer: President and COO | Purchase · 2 lots | 2,073 | $6.05 | 40,387 |
| Sep 4, 2026 | Phillip P. Chandirector, officer: Chief Executive Officer | Purchase | 200,000 | $0.3500 | 1,944,432 |
| Jun 15, 2026 | Peter J. Marianiofficer: Chief Financial Officer | Purchase | 100,000 | $0.4400 | 638,113 |
| Jun 12, 2026 | Phillip P. Chandirector, officer: Chief Executive Officer | Purchase | 251,136 | $0.4000 | 1,734,099 |
| Jun 15, 2026 | Phillip P. Chandirector, officer: Chief Executive Officer | Purchase | 10,333 | $0.4300 | 1,744,432 |
House and Senate disclosures
Not reported.